will relapse within the first three years following

initial treatment.5

70%70%of patients with ovariancancer

Understanding Ovarian Cancer in Europe

For more information, visit www.clovisoncology.com

After initial therapy, many women’s disease will still recur (return).5

Understanding Maintenance Treatment

1. World Health Organization. GLOBOCAN: estimated cancer incidence, mortality and prevalence worldwide in 2018. Available at http://gco.iarc.fr/. (last accessed September 2019).2. McPhail S, et al. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112:S108—S115 3. Cancer in Germany. Available at http://www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_chapters_2009_2010/cancer_c56.pdf?__blob=publicationFile. (last accessed September 2019). 4. Llueca A. Short commentary about the ovarian cancer in the Spanish province of Castellon. Trends Gynecol Oncol. 2016;1(1):1000102 5. Ledermann J et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi24-32.6. Coleman R, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10106):1949—1961. 7. Clovis Oncology, Inc. Press release on January 2019. Clovis Oncology announces european commission authorization of Rubraca® (rucaparib) tablets as maintenance treatment for women with relapsed ovarian cancer. Last accessed September 2019 from https://s22.q4cdn.com/778348918/files/doc_news/Clovis-Oncology-Announces-European-Commission-Authorization-of-Rubraca-rucaparib-Tablets-as-Maintenance-Treatment-for-Women-with-Relapsed-Ovarian-Cancer.pdf 8. Understanding maintainence therapy. Available at https://www.cancer.net/navigating-cancer-care/how-cancer-treated/understanding-maintenance-therapy. (last accessed September 2019).

67,771

The 6th most common cancer among women,

with an estimated

new cases in 2018.1

Who Can Receive Maintenance Treatment?All eligible recurrent ovarian cancer patients currently in response to a platinum-based therapy, regardless of a BRCA mutation.6

New therapies may provide more options for women whose disease recursA variety of treatments can help to manage ovarian cancer when it recurs. For some women with platinum-sensitive, recurrent ovarian cancer, maintenance treatment has significantly extended the time following treatment that a woman's ovarian cancer does not get worse.6,7

What is Maintenance Treatment? Maintenance treatment is used to avoid or slow the return of cancer if it is in complete or partial remission after completing chemotherapy treatment.8

Five Countries at a Glance

Germany UK France Italy Spain

6,781 6,407 4,985 4,981 3,427

5,400 4,155 3,927 3,261 2,123

Estimated new cases of ovarian cancer in 20181

Estimated number of ovarian cancer deaths in 20181

Approximately

5th

leading cause of cancer deaths among women,

with an estimated 44,576 deaths

annually.1

63–69 is the average

age range of diagnosis across

Europe.2–4